Takeda continuing divestment spree by monetising unwanted oncology IP
The Japanese company is leading the pack in trend of commercialising de-prioritised assets
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.